Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Alemtuzumab; Calcineurin Inhibitors

Criteria

Inclusion Criteria:

• received a renal transplant, induction with Campath-1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone.

Exclusion Criteria:

• Recipients of HLA-identical living-donor renal transplants;

• PRA value >20% within 30 days of transplant;

• GFR <40ml/min;

• multi-organ transplant;